The influence of thrombotic risk factors when oral contraceptives are prescribed a control‐only study

Objectives. The aim of this study was to assess preferential prescribing of OC according to different thrombotic risk factors.

[1]  Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components , 1996 .

[2]  K D MacRae,et al.  The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women. , 1996, Contraception.

[3]  W. Spitzer,et al.  Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study , 1996, BMJ.

[4]  W. Spitzer,et al.  Third generation oral contraceptives and risk of myocardial infarction: an international case-control study , 1996, BMJ.

[5]  T. Farley,et al.  Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease , 1995 .

[6]  H. Jick,et al.  Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen components , 1995, The Lancet.

[7]  J. Vandenbroucke,et al.  Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen , 1995, The Lancet.

[8]  T. Farley,et al.  Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. , 1995, Lancet.

[9]  O. Lidegaard.  [Use of oral contraceptives in Denmark 1980-1990 and smoking habits among fertile women in 1990]. , 1993, Ugeskrift for laeger.

[10]  Ø. Lidegaard,et al.  Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. , 1993, BMJ.

[11]  M. Thorogood,et al.  Oral contraceptive prescribing in the presence of risk factors. , 1991 .

[12]  M. Thorogood,et al.  Trends in use of oral contraceptives in Britain. , 1990 .

[13]  K. Overgaard,et al.  The Oral Contraceptive User , 1988, Acta obstetricia et gynecologica Scandinavica.

[14]  O. Lidegaard.  [Use of oral contraceptives in Denmark in 1983]. , 1984, Ugeskrift for laeger.

[15]  O. Lidegaard.  Oral contraception in Denmark in 1983 , 1984 .

[16]  G. Eklund,et al.  ORAL CONTRACEPTIVES AND THROMBOEMBOLIC DISEASE: EFFECTS OF LOWERING ŒSTROGEN CONTENT , 1980, The Lancet.

[17]  B. Westerholm,et al.  Oral contraceptives and thromboembolic disease. Swedish experience. , 2009 .

[18]  A. Masi,et al.  THROMBOEMBOLISM AND ORAL CONTRACEPTIVES: AN EPIDEMIOLOGIC CASE-CONTROL STUDY , 1970 .

[19]  A. Masi,et al.  Thromboembolism and oral contraceptives: an epidemiologic case-control study. , 1969, American journal of epidemiology.

[20]  R. Doll,et al.  Investigation of Relation between Use of Oral Contraceptives and Thromboembolic Disease. A Further Report , 1969, British medical journal.

[21]  D. W. Calhoun,et al.  Oral contraceptives and thromboembolic disease. , 1968, JAMA.

[22]  M. Kataria.  Oral contraceptives and thromboembolic disease * , 1963, British medical journal.